avapro has been researched along with Atherogenesis in 14 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atherosclerosis is a chronic inflammatory disease in which the renin-angiotensin-aldosterone system plays an important role." | 1.36 | Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice. ( Chen, Y; Cheng, X; Ding, YJ; Liao, MY; Liao, YH; Tang, TT; Xie, JJ; Yao, R; Yu, X, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S | 1 |
| Wang, K | 1 |
| Xu, G | 1 |
| Ji, J | 1 |
| Qin, C | 1 |
| Li, L | 1 |
| Li, J | 1 |
| Yi, J | 1 |
| Liu, H | 1 |
| Lei, H | 1 |
| Georgescu, A | 2 |
| Alexandru, N | 2 |
| Nemecz, M | 1 |
| Titorencu, I | 2 |
| Popov, D | 2 |
| Zhao, Y | 1 |
| Fukao, K | 1 |
| Zhao, S | 1 |
| Watanabe, A | 1 |
| Hamada, T | 1 |
| Yamasaki, K | 1 |
| Shimizu, Y | 1 |
| Kubo, N | 1 |
| Ukon, N | 1 |
| Nakano, T | 1 |
| Tamaki, N | 1 |
| Kuge, Y | 1 |
| Jiang, Y | 1 |
| Jiang, LL | 1 |
| Maimaitirexiati, XM | 1 |
| Zhang, Y | 1 |
| Wu, L | 1 |
| Yao, R | 1 |
| Cheng, X | 1 |
| Chen, Y | 1 |
| Xie, JJ | 1 |
| Yu, X | 1 |
| Liao, MY | 1 |
| Ding, YJ | 1 |
| Tang, TT | 1 |
| Liao, YH | 1 |
| Iwai, M | 1 |
| Kanno, H | 1 |
| Senba, I | 1 |
| Nakaoka, H | 1 |
| Moritani, T | 1 |
| Horiuchi, M | 1 |
| Ma, C | 1 |
| Lu, XC | 1 |
| Fan, L | 1 |
| Luo, Y | 1 |
| Yang, B | 1 |
| Gao, Y | 1 |
| Liu, XF | 1 |
| Andrei, E | 1 |
| Dragan, E | 1 |
| Tarziu, C | 1 |
| Ghiorghe, S | 1 |
| Badila, E | 1 |
| Bartos, D | 1 |
| Wang, L | 1 |
| Huang, XS | 1 |
| Zhou, YL | 1 |
| Chen, JY | 1 |
| Lin, SG | 1 |
| Cipollone, F | 1 |
| Fazia, ML | 1 |
| Mezzetti, A | 1 |
| Morawietz, H | 1 |
| Erbs, S | 1 |
| Holtz, J | 1 |
| Schubert, A | 1 |
| Krekler, M | 1 |
| Goettsch, W | 1 |
| Kuss, O | 1 |
| Adams, V | 1 |
| Lenk, K | 1 |
| Mohr, FW | 1 |
| Schuler, G | 1 |
| Hambrecht, R | 1 |
| Vyssoulis, GP | 1 |
| Karpanou, EA | 1 |
| Kyvelou, SM | 1 |
| Adamopoulos, DN | 1 |
| Antonakoudis, GC | 1 |
| Deligeorgis, AD | 1 |
| Cokkinos, DV | 1 |
| Stefanadis, CI | 1 |
| Nussberger, J | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Pellegrin, M | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
1 review available for avapro and Atherogenesis
| Article | Year |
|---|---|
Role of angiotensin II receptor blockers in atherosclerotic plaque stability.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Caroti | 2006 |
3 trials available for avapro and Atherogenesis
| Article | Year |
|---|---|
[Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atheroscler | 2005 |
Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Blood Pressure; Choles | 2006 |
Beneficial effect of angiotensin II type 1 receptor blocker antihypertensive treatment on arterial stiffness: the role of smoking.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Blood Flo | 2008 |
10 other studies available for avapro and Atherogenesis
| Article | Year |
|---|---|
The intervention effect of zinc supplementation on irbesartan treatment for atherosclerosis of ApoE-/- mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aor | 2016 |
Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Atheroscle | 2018 |
Irbesartan administration therapeutically influences circulating endothelial progenitor cell and microparticle mobilization by involvement of pro-inflammatory cytokines.
Topics: Animals; Arteries; Atherosclerosis; Biphenyl Compounds; Cell Adhesion; Cell-Derived Microparticles; | 2013 |
Irbesartan attenuates atherosclerosis in Watanabe heritable hyperlipidemic rabbits: noninvasive imaging of inflammation by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Autoradiography; Biphenyl Compounds; Body Weight; | 2015 |
Irbesartan attenuates TNF-α-induced ICAM-1, VCAM-1, and E-selectin expression through suppression of NF-κB pathway in HUVECs.
Topics: Atherosclerosis; Biphenyl Compounds; Human Umbilical Vein Endothelial Cells; Humans; Intercellular A | 2015 |
Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Bipheny | 2010 |
Irbesartan increased PPARγ activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction.
Topics: Adipocytes, White; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipop | 2011 |
[Irbesartan regulates inflammatory gene expressions related to atherosclerosis in EA.hy926 cells].
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Cell Line; Cytoprotect | 2011 |
Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biphenyl Compounds; Blood Pressur | 2012 |
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Topics: Amides; Amlodipine; Animals; Antihypertensive Agents; Apolipoproteins E; Atenolol; Atherosclerosis; | 2008 |